Citizen Petition from Haystack Project, Inc., et al.

NonrulemakingOtherFDA-2026-P-3666-0001
🔔 Subscribe
Comments
0
Awaiting comments
Deadline
--
Net supportiSupport minus oppose · campaigns included
+100%
+100% excluding campaigns
Document

Details

The document's own metadata, straight from regulations.gov.

Posted
Apr 7, 2026
Comment period
Apr 7, 2026 – ?
Agency
Food and Drug Administration (FDA)
Analysis

Overview

No comments yet.

Comments

Explorer

Every mirrored comment — filter by stance, campaign, or issue.

4 comments from the past week

Comments older than a week are open to everyone. Read this week's arrivals — with stance, commenter type, and AI summaries — on the paid plan.

  • Professor Matthew Simunovic, an academic and vitreoretinal surgeon, supports the Haystack Project's petition for rulemaking regarding the evaluation of "well-controlled" clinical investigations in rare diseases. He argues that regulatory frameworks should allow for flexibility in outcome measures, specifically advocating for the use of validated psychophysical assessments over the repeated development of complex, bespoke functional assessments.

  • Dr. Jason J. Begalke supports the Haystack Project's petition to modernize FDA regulatory frameworks for rare diseases. He argues that the current reliance on large-scale randomized controlled trials is unsuitable for small patient populations and advocates for context-driven evidence like natural history controls and disease-specific endpoints.

© 2026 Government Context · not affiliated with any U.S. government agencyPrivacyTermsDockets